Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Cannabis‐based medicines probably leads to higher PGIC of much improved or very much improved compared with placebo medication (moderate certainty).
Cannabis‐based medicines showed no clear difference in withdrawals due to adverse events compared with placebo medication (moderate certainty).
Cannabis‐based medicines showed no clear difference in mean pain intensity (Numeric Rating Scale 0–10) compared with placebo medication (moderate certainty).
Cannabis‐based medicines showed no clear difference in daily maintenance opioid dosage (mg morphine equivalent) compared with placebo medication (low certainty).
Cannabis‐based medicines showed no clear difference in daily breakthrough opioid dosage (mg morphine equivalent) compared with placebo medication (moderate certainty).
Cannabis‐based medicines showed no clear difference in participants experiencing any serious adverse event compared with placebo medication (moderate certainty).
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care probably leads to lower clinical worsening: participants admitted to hospital or deceased at… compared with standard care (plus/minus placebo) (moderate certainty).
The review found no eligible studies for this question.
Remdesivir and standard care may leads to lower serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in in‐hospital mortality at up to day 150 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care probably leads to higher clinical improvement: participants alive and ready to be discharged… compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care probably leads to lower clinical worsening: time to new need for invasive mechanical… compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).